Country	NETHERLAND	USA				USA					USA		Germany				Japan	
Company	Concept Medical	Abbott				Boston Scientific					Medtronic		Biotronik				TERUMO	
Done by Product	Abluminus DES +	Xience V				Promus / Synergy					Resolute		Orsiro				UltiMaster	
Trial / Registry	en-ABL	SPIRIT III		SPIRIT IV		PLATINUM WORKHORSE Trial		PLATINUM PLUS clinical trial		The Evolve II study	RESOLUTE (R-AC)		BIOSCIENCE Trial		BIOFLOW - V		RCT : CENTURY II	
Objective	To evaluate the safety and efficacy of the AbluminusDES+ in all-comers population with minimal exclusion criteria, Multicenter,prospective,all-comers on going registry performed in 31centers.	This was a larger randomized controlled study conducted in the USA and Japan involving 1002 patients of similar background to the patient population of SPIRIT II, comparing Xience V with Taxus in a 2:1 ratio [15]. The premise was that the everolimus-eluting stent will be similar or superior to the paclitaxel-eluting stent		SPIRIT IV is a large-scale trial seeking to compare clinical end points between Xience V and Taxus in a more complex patient population [23]. A total of 3687 patients were enrolled in this single-blind, prospective, multicenter US trial randomizing patients to Xience V or Taxus in a 2:1 fashion		PLATINUM Workhorse trial comparing the safety and effectiveness of the Promus Element Everolimus-Eluting Platinum Chromium (PtCr) Coronary Stent System to the Promus (Xience V) Everolimus-Eluting Coronary Stent System		Twelve-month results of a prospective, multicentre trial to assess the everolimus-eluting coronary stent system (PROMUS Element): the PLATINUM PLUS all-comers randomised trial		The EVOLVE II diabetes substudy is a prospective, multicentre study conducted as part of the EVOLVE II, randomised, controlled, singleblind, non-inferiority trial	In the RESOLUTE All-Comers (R-AC) trial, a randomized trial comparing the Resolute ZES with the Xience V® EES for treatment of patients with coronary lesions who had minimal exclusion criteria, there were similar safety and efficacy outcomes between the two stents		Prospective, all-comers, multi-center, randomized, non-inferiority design, In this 2,119 patient, randomized, all-comers trial, Orsiro demonstrated non-inferiority to Xience Prime for the primary endpoint at 12 months. A similar trend was shown throughout 24 months		BIOFLOW V (Biotronik Prospective Randomized Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in the Treatment of Subjects with Up to Three De Novo or Restenotic Coronary Artery Lesions V) was an international randomized trial comparing coronary revascularization with BP SES and DP EES		To assess the long-term safety and efficacy of a sirolimus-eluting stent with bioresorbable polymer (BP-SES; Ultimaster), in comparison to a benchmark everolimuseluting, permanentpolymersten t(PP-EES; Xience), in a prespecifiedsubgroup of patients with multivessel coronary artery disease (MVD) enrolled in the CENTURY II trial.	
Total patients	2500	1002		3687		1530		2980		466	2292		2119		1134		1123	
Products Involved	Abluminus DES +	Xience V	Taxus	Xience V	Taxus	Promus Element	Taxus	Promus Element	Xience Prime	Synergy	Resolute	Xience V	Orsiro	Xience Prime	Orsiro	Xience	UltiMaster	Xience
No. of patients enrolled	2500	669	333	2458	1229	765	765	1952	1028	466	1140	1152	1063	1056	884	450	562	557
Result @ 1yr follow - up	1 Year follow up	1 Year follow up		1 Year follow up		1 Year follow up		1 Year follow up		1 Year follow up	1 Year follow up		1 Year follow up		1 Year follow up		1 Year follow up	
MACE	2.80%	-	-	4.20%	6.00%	3.30%	3%	4.70%	3.90%	-	8.60%	9.80%	6.70%	6.70%	-	-	-	-
Cardiac Death	1.00%	0.50%	0.30%	0.40%	0.40%	-	-	1.10%	1.00%	0.70%	1.30%	1.70%	-	-	1.10%	1.20%	0.91%	1.06%
TVR / TLR	1.40%	6.10%	7.50%	2.50%	4.60%	1.90%	1.90%	2.00%	1.60%	TVR :- 5.3% / TLR :- 4.4%	TLR - 3.9% / TVR - 4.9%	TLR - 3.4% / TVR - 4.8%	3.40%	2.40%	2.00%	2.40%	2.72%	2.18%
ST	0.60%	0.80%	0.60%	0.29%	1.06%	0.50%	0.70%	0.80%	0.50%	1.10%	1.60%	0.70%	2.80%	2.80%	0.10%	1.20%	0.91%	0.91%
Result @ 2yr follow - up	2 Year follow up	2 Year follow up		2 Year follow up		2 Year follow up		-		2 Year follow up	2 Year follow up		2 Year follow up		2 Year follow up		-	
MACE	3.00%	7.70%	13.80%	7.10%	10.10%	4.20%	6.30%	-	-	-	9.70%	9.60%	10.50%	10.40%	-	-	-	-
Cardiac Death	1.10%	1.10%	1.30%	0.90%	1.30%	-	-	-	-	1.50%	-	-	-	-	1.10%	1.20%	-	-
TVR / TLR	1.50%	6.10%	11.30%	4.50%	6.90%	2.40%	4%	-	-	TVR :- 8.6% / TLR :- 6.8%	5.40%	5.20%	6%	5.10%	2.60%	4.90%	-	-
ST	0.60%	1.10%	1.70%	0.42%	1.23%	1.20%	1.60%	-	-	1.10%	1.90%	1.20%	3.90%	4.90%	0.10%	1.20%	-	-
Result @ 3yr follow - up	3 Year follow up	3 Year follow up		-		3 Year follow up		-		-	3 Year follow up		-		3 Year follow up		-	
MACE	3.80%	9.70%	16.40%	-	-	5.60%	7.50%	-	-	-	10.30%	9.90%	-	-	11.90%	18.00%	-	-
Cardiac Death	1.80%	1.40%	1.60%	-	-	-	-	-	-	-	-	-	-	-	1.10%	1.20%	-	-
TVR / TLR	1.70%	6.10%	11.30%	-	-	3.20%	4.60%	-	-	-	5.60%	5.50%	-	-	3.40%	6.90%	-	-
ST	0.60%	1.10%	1.70%	-	-	1.20%	1.60%	-	-	-	2.10%	1.60%	-	-	0.10%	1.20%	-	-